{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T01:13:37Z","timestamp":1788484417209,"version":"build-2803163510"},"reference-count":54,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T00:00:00Z","timestamp":1785196800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000069","name":"National Institute of Arthritis and Musculoskeletal and Skin Diseases","doi-asserted-by":"publisher","award":["R01 AR081487"],"award-info":[{"award-number":["R01 AR081487"]}],"id":[{"id":"10.13039\/100000069","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Institutes of Health National Cancer Institute","doi-asserted-by":"publisher","award":["R01 CA294365"],"award-info":[{"award-number":["R01 CA294365"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Letters"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.canlet.2026.218768","type":"journal-article","created":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T15:39:21Z","timestamp":1785253161000},"page":"218768","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Elevated FN14 expression promotes proliferation, chemoresistance, and impairment of differentiation in rhabdomyosarcoma"],"prefix":"10.1016","volume":"658","author":[{"given":"Anh Tuan","family":"Vuong","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoxiao","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Niraj K.","family":"Sah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Phuong T.","family":"Ho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashok","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.canlet.2026.218768_bib1","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1002\/pbc.24435","article-title":"Children's oncology Group's 2013 blueprint for research: soft tissue sarcomas","volume":"60","author":"Hawkins","year":"2013","journal-title":"Pediatr. Blood Cancer"},{"key":"10.1016\/j.canlet.2026.218768_bib2","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1038\/nrc3961","article-title":"Probing for a deeper understanding of rhabdomyosarcoma: insights from complementary model systems","volume":"15","author":"Kashi","year":"2015","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.canlet.2026.218768_bib3","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1186\/1471-2407-14-139","article-title":"Pharmacological inhibition of EZH2 as a promising differentiation therapy in embryonal RMS","volume":"14","author":"Ciarapica","year":"2014","journal-title":"BMC Cancer"},{"key":"10.1016\/j.canlet.2026.218768_bib4","doi-asserted-by":"crossref","first-page":"4323","DOI":"10.1111\/febs.12421","article-title":"Mechanisms of impaired differentiation in rhabdomyosarcoma","volume":"280","author":"Keller","year":"2013","journal-title":"FEBS J."},{"key":"10.1016\/j.canlet.2026.218768_bib5","doi-asserted-by":"crossref","DOI":"10.1016\/j.redox.2019.101124","article-title":"Genetics, epigenetics and redox homeostasis in rhabdomyosarcoma: emerging targets and therapeutics","volume":"25","author":"Pal","year":"2019","journal-title":"Redox Biol."},{"key":"10.1016\/j.canlet.2026.218768_bib6","doi-asserted-by":"crossref","first-page":"1591","DOI":"10.1038\/s41416-025-03130-1","article-title":"Relapsed rhabdomyosarcoma: treatment recommendations from the European pediatric soft tissue sarcoma study group (EpSSG)","volume":"133","author":"Defachelles","year":"2025","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.canlet.2026.218768_bib7","doi-asserted-by":"crossref","DOI":"10.3390\/cancers15215269","article-title":"Rhabdomyosarcoma: current therapy, challenges, and future approaches to treatment strategies","volume":"15","author":"Zarrabi","year":"2023","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.canlet.2026.218768_bib8","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1038\/nrd2488","article-title":"The TWEAK-Fn14 cytokine-receptor axis: discovery, biology and therapeutic targeting","volume":"7","author":"Winkles","year":"2008","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.canlet.2026.218768_bib9","doi-asserted-by":"crossref","first-page":"3346","DOI":"10.1038\/sj.onc.1209357","article-title":"Transcriptional profiling suggests that Barrett's metaplasia is an early intermediate stage in esophageal adenocarcinogenesis","volume":"25","author":"Wang","year":"2006","journal-title":"Oncogene"},{"key":"10.1016\/j.canlet.2026.218768_bib10","doi-asserted-by":"crossref","first-page":"2132","DOI":"10.1002\/ijc.22898","article-title":"Identification of Fn14\/TWEAK receptor as a potential therapeutic target in esophageal adenocarcinoma","volume":"121","author":"Watts","year":"2007","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.canlet.2026.218768_bib11","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.1093\/carcin\/bgr182","article-title":"Overexpression of Fn14 promotes androgen-independent prostate cancer progression through MMP-9 and correlates with poor treatment outcome","volume":"32","author":"Huang","year":"2011","journal-title":"Carcinogenesis"},{"key":"10.1016\/j.canlet.2026.218768_bib12","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.canlet.2011.09.016","article-title":"Elevated fibroblast growth factor-inducible 14 expression promotes gastric cancer growth via nuclear factor-kappaB and is associated with poor patient outcome","volume":"314","author":"Kwon","year":"2012","journal-title":"Cancer Lett."},{"key":"10.1016\/j.canlet.2026.218768_bib13","doi-asserted-by":"crossref","first-page":"4407","DOI":"10.1158\/1078-0432.CCR-07-0109","article-title":"Emmprin and survivin predict response and survival following cisplatin-containing chemotherapy in patients with advanced bladder cancer","volume":"13","author":"Als","year":"2007","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.canlet.2026.218768_bib14","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.1038\/jid.2012.402","article-title":"The TWEAK receptor Fn14 is a therapeutic target in melanoma: immunotoxins targeting Fn14 receptor for malignant melanoma treatment","volume":"133","author":"Zhou","year":"2013","journal-title":"J. Invest. Dermatol."},{"key":"10.1016\/j.canlet.2026.218768_bib15","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1158\/1541-7786.MCR-08-0005","article-title":"The fibroblast growth factor-inducible 14 receptor is highly expressed in HER2-positive breast tumors and regulates breast cancer cell invasive capacity","volume":"6","author":"Willis","year":"2008","journal-title":"Mol. Cancer Res."},{"key":"10.1016\/j.canlet.2026.218768_bib16","doi-asserted-by":"crossref","first-page":"9535","DOI":"10.1158\/0008-5472.CAN-06-0418","article-title":"Increased fibroblast growth factor-inducible 14 expression levels promote glioma cell invasion via Rac1 and nuclear factor-kappaB and correlate with poor patient outcome","volume":"66","author":"Tran","year":"2006","journal-title":"Cancer Res."},{"key":"10.1016\/j.canlet.2026.218768_bib17","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1158\/1078-0432.CCR-09-1929","article-title":"Antibodies to TWEAK receptor inhibit human tumor growth through dual mechanisms","volume":"16","author":"Culp","year":"2010","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.canlet.2026.218768_bib18","doi-asserted-by":"crossref","DOI":"10.1016\/j.isci.2025.112714","article-title":"The TWEAK\/Fn14 signaling mediates skeletal muscle wasting during cancer cachexia","volume":"28","author":"Tomaz da Silva","year":"2025","journal-title":"iScience"},{"key":"10.1016\/j.canlet.2026.218768_bib19","doi-asserted-by":"crossref","first-page":"1758","DOI":"10.3390\/cancers12071758","article-title":"Recent advances and challenges in the treatment of rhabdomyosarcoma","volume":"12","author":"Miwa","year":"2020","journal-title":"Cancers (Basel)"},{"issue":"1","key":"10.1016\/j.canlet.2026.218768_bib20","doi-asserted-by":"crossref","DOI":"10.1038\/s41572-018-0051-2","article-title":"Rhabdomyosarcoma","volume":"5","author":"Skapek","year":"2019","journal-title":"Nat. Rev. Dis. Primers"},{"key":"10.1016\/j.canlet.2026.218768_bib21","doi-asserted-by":"crossref","first-page":"10327","DOI":"10.1074\/jbc.M511131200","article-title":"Tumor necrosis factor-like weak inducer of apoptosis inhibits skeletal myogenesis through sustained activation of nuclear factor-kappaB and degradation of MyoD protein","volume":"281","author":"Dogra","year":"2006","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.canlet.2026.218768_bib22","doi-asserted-by":"crossref","DOI":"10.1126\/scisignal.2003086","article-title":"TWEAK and cIAP1 regulate myoblast fusion through the noncanonical NF-kappaB signaling pathway","volume":"5","author":"Enwere","year":"2012","journal-title":"Sci. Signal."},{"key":"10.1016\/j.canlet.2026.218768_bib23","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.187825","article-title":"Fibroblast growth factor-inducible 14 regulates satellite cell self-renewal and expansion during skeletal muscle repair","volume":"10","author":"Tomaz da Silva","year":"2025","journal-title":"JCI Insight"},{"key":"10.1016\/j.canlet.2026.218768_bib24","doi-asserted-by":"crossref","DOI":"10.26508\/lsa.202302312","article-title":"Fn14 promotes myoblast fusion during regenerative myogenesis","volume":"6","author":"Tomaz da Silva","year":"2023","journal-title":"Life Sci. Alliance"},{"key":"10.1016\/j.canlet.2026.218768_bib25","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1111\/j.1600-065X.2011.01054.x","article-title":"TWEAK\/Fn14 pathway: an immunological switch for shaping tissue responses","volume":"244","author":"Burkly","year":"2011","journal-title":"Immunol. Rev."},{"key":"10.1016\/j.canlet.2026.218768_bib26","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/j.cytogfr.2013.12.004","article-title":"The TWEAK-Fn14 pathway: a potent regulator of skeletal muscle biology in health and disease","volume":"25","author":"Tajrishi","year":"2014","journal-title":"Cytokine Growth Factor Rev."},{"key":"10.1016\/j.canlet.2026.218768_bib27","doi-asserted-by":"crossref","DOI":"10.21769\/BioProtoc.2351","article-title":"Soft agar colony formation assay as a hallmark of carcinogenesis","volume":"7","author":"Du","year":"2017","journal-title":"Bio Protoc"},{"key":"10.1016\/j.canlet.2026.218768_bib28","doi-asserted-by":"crossref","first-page":"12976","DOI":"10.1074\/jbc.M114.563478","article-title":"Regulation of fibroblast growth factor-inducible 14 (Fn14) expression levels via ligand-independent lysosomal degradation","volume":"289","author":"Gurunathan","year":"2014","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.canlet.2026.218768_bib29","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2022.935086","article-title":"Targeting fibroblast growth factor (FGF)-inducible 14 (Fn14) for tumor therapy","volume":"13","author":"Zaitseva","year":"2022","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.canlet.2026.218768_bib30","doi-asserted-by":"crossref","first-page":"32261","DOI":"10.1074\/jbc.M113.493536","article-title":"Structural basis and targeting of the interaction between fibroblast growth factor-inducible 14 and tumor necrosis factor-like weak inducer of apoptosis","volume":"288","author":"Dhruv","year":"2013","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.canlet.2026.218768_bib31","doi-asserted-by":"crossref","DOI":"10.1016\/j.jmb.2021.167378","article-title":"Apoptosis, Pyroptosis, and Necroptosis-Oh My! The Many Ways a Cell Can Die","volume":"434","author":"Ketelut-Carneiro","year":"2022","journal-title":"J. Mol. Biol."},{"key":"10.1016\/j.canlet.2026.218768_bib32","doi-asserted-by":"crossref","first-page":"1566","DOI":"10.1016\/S1470-2045(19)30617-5","article-title":"Vinorelbine and continuous low-dose cyclophosphamide as maintenance chemotherapy in patients with high-risk rhabdomyosarcoma (RMS 2005): a multicentre, open-label, randomised, phase 3 trial","volume":"20","author":"Bisogno","year":"2019","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.canlet.2026.218768_bib33","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aan4470","article-title":"MEK inhibition induces MYOG and remodels super-enhancers in RAS-driven rhabdomyosarcoma","volume":"10","author":"Yohe","year":"2018","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.canlet.2026.218768_bib34","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1007\/s10555-020-09860-3","article-title":"Signaling pathways in rhabdomyosarcoma invasion and metastasis","volume":"39","author":"Ramadan","year":"2020","journal-title":"Cancer Metastasis Rev."},{"key":"10.1016\/j.canlet.2026.218768_bib35","doi-asserted-by":"crossref","first-page":"5940","DOI":"10.1158\/1078-0432.CCR-13-0850","article-title":"Dual blockade of the PI3K\/AKT\/mTOR (AZD8055) and RAS\/MEK\/ERK (AZD6244) pathways synergistically inhibits rhabdomyosarcoma cell growth in vitro and in vivo","volume":"19","author":"Renshaw","year":"2013","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.canlet.2026.218768_bib36","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1038\/s41580-019-0173-8","article-title":"Mitochondria as multifaceted regulators of cell death","volume":"21","author":"Bock","year":"2020","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"10.1016\/j.canlet.2026.218768_bib37","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1038\/s41392-024-01839-8","article-title":"Mitochondrial dysfunction: mechanisms and advances in therapy","volume":"9","author":"Zong","year":"2024","journal-title":"Signal Transduct. Targeted Ther."},{"key":"10.1016\/j.canlet.2026.218768_bib38","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.3390\/cells14141115","article-title":"Integrative multi-omics profiling of rhabdomyosarcoma subtypes reveals distinct molecular pathways and biomarker signatures","volume":"14","author":"Osama","year":"2025","journal-title":"Cells"},{"key":"10.1016\/j.canlet.2026.218768_bib39","doi-asserted-by":"crossref","first-page":"2757","DOI":"10.1016\/j.cell.2025.03.008","article-title":"PAX translocations remodel mitochondrial metabolism through altered leucine usage in rhabdomyosarcoma","volume":"188","author":"Kalita","year":"2025","journal-title":"Cell"},{"key":"10.1016\/j.canlet.2026.218768_bib40","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1007\/s00018-023-04969-4","article-title":"Staufen1 controls mitochondrial metabolism via HIF2alpha in embryonal rhabdomyosarcoma and promotes tumorigenesis","volume":"80","author":"Almasi","year":"2023","journal-title":"Cell. Mol. Life Sci."},{"key":"10.1016\/j.canlet.2026.218768_bib41","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1016\/j.ccr.2013.11.002","article-title":"Targeting oxidative stress in embryonal rhabdomyosarcoma","volume":"24","author":"Chen","year":"2013","journal-title":"Cancer Cell"},{"key":"10.1016\/j.canlet.2026.218768_bib42","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a025650","article-title":"Rhabdomyosarcoma: current challenges and their implications for developing therapies","volume":"4","author":"Hettmer","year":"2014","journal-title":"Cold Spring Harb. Perspect. Med."},{"key":"10.1016\/j.canlet.2026.218768_bib43","doi-asserted-by":"crossref","first-page":"5638","DOI":"10.1038\/s41467-024-50071-z","article-title":"TWEAK\/Fn14 signalling driven super-enhancer reprogramming promotes pro-metastatic metabolic rewiring in triple-negative breast cancer","volume":"15","author":"Sim","year":"2024","journal-title":"Nat. Commun."},{"key":"10.1016\/j.canlet.2026.218768_bib44","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1007\/s10585-014-9653-6","article-title":"FN14 expression correlates with MET in NSCLC and promotes MET-driven cell invasion","volume":"31","author":"Whitsett","year":"2014","journal-title":"Clin. Exp. Metastasis"},{"key":"10.1016\/j.canlet.2026.218768_bib45","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1002\/pbc.24118","article-title":"Rhabdomyosarcoma: review of the Children's oncology group (COG) soft-tissue sarcoma committee experience and rationale for current COG studies","volume":"59","author":"Malempati","year":"2012","journal-title":"Pediatr. Blood Cancer"},{"key":"10.1016\/j.canlet.2026.218768_bib46","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1038\/s41416-025-03087-1","article-title":"High expression of the cachexia-related protein Fn14 in esophageal squamous cell carcinoma correlates with poor chemotherapy response and anti-Fn14 therapy decreases chemotherapeutic resistance","volume":"133","author":"Adachi","year":"2025","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.canlet.2026.218768_bib47","doi-asserted-by":"crossref","first-page":"583","DOI":"10.3892\/ijo.2013.2211","article-title":"TWEAK\/Fn14 signaling mediates gastric cancer cell resistance to 5-fluorouracil via NF-kappaB activation","volume":"44","author":"Kwon","year":"2014","journal-title":"Int. J. Oncol."},{"key":"10.1016\/j.canlet.2026.218768_bib48","doi-asserted-by":"crossref","first-page":"19985","DOI":"10.1074\/jbc.M114.568626","article-title":"DNA methyltransferase 3a and mitogen-activated protein kinase signaling regulate the expression of fibroblast growth factor-inducible 14 (Fn14) during denervation-induced skeletal muscle atrophy","volume":"289","author":"Tajrishi","year":"2014","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.canlet.2026.218768_bib49","first-page":"453","article-title":"Revealing the landscape of targeting mitochondrial functions and behaviors to overcome cancer chemoresistance","volume":"5","author":"Zhang","year":"2025","journal-title":"J. Natl. Cancer Cent."},{"key":"10.1016\/j.canlet.2026.218768_bib50","first-page":"634","article-title":"Mitochondrial determinants of chemoresistance","volume":"2","author":"Bokil","year":"2019","journal-title":"Cancer Drug Resist"},{"key":"10.1016\/j.canlet.2026.218768_bib51","article-title":"Mitochondrion: main organelle in orchestrating cancer escape from chemotherapy","volume":"7","author":"Mostafavi","year":"2024","journal-title":"Cancer Rep (Hoboken)"},{"key":"10.1016\/j.canlet.2026.218768_bib52","doi-asserted-by":"crossref","first-page":"3627","DOI":"10.1038\/s44319-024-00197-4","article-title":"The IRE1alpha\/XBP1 signaling axis drives myoblast fusion in adult skeletal muscle","volume":"25","author":"Joshi","year":"2024","journal-title":"EMBO Rep."},{"key":"10.1016\/j.canlet.2026.218768_bib53","doi-asserted-by":"crossref","first-page":"1714","DOI":"10.1038\/s41388-026-03767-z","article-title":"TAK1 is a key regulator of oncogenic signaling and differentiation blockade in rhabdomyosarcoma","volume":"45","author":"Vuong","year":"2026","journal-title":"Oncogene"},{"key":"10.1016\/j.canlet.2026.218768_bib54","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1038\/s42003-026-10184-1","article-title":"Targeting the IRE1alpha-XBP1 signaling axis impairs tumor growth and promotes myogenic differentiation in rhabdomyosarcoma","volume":"9","author":"Vuong","year":"2026","journal-title":"Commun. Biol."}],"container-title":["Cancer Letters"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S030438352600532X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S030438352600532X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T00:45:31Z","timestamp":1788482731000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S030438352600532X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":54,"alternative-id":["S030438352600532X"],"URL":"https:\/\/doi.org\/10.1016\/j.canlet.2026.218768","relation":{},"ISSN":["0304-3835"],"issn-type":[{"value":"0304-3835","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Elevated FN14 expression promotes proliferation, chemoresistance, and impairment of differentiation in rhabdomyosarcoma","name":"articletitle","label":"Article Title"},{"value":"Cancer Letters","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.canlet.2026.218768","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"218768"}}